Navigation Links
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Date:1/29/2008

s non-executive Chair

of the Board of Directors.

Financial Results:

All amounts are in Canadian dollars unless otherwise indicated.

For the year ended November 30, 2007, the Company recorded a net loss of $11,057,039 compared to a net loss of $6,444,189 for the year ended November 30, 2006. The increase in net loss was the result of higher research and development, general administrative and foreign exchange expenses and lower revenues, partially offset by lower interest expense and the absence of a loss on extinguishment of debt. For the three-month period ended November 30, 2007, the Company recorded a net loss of $2,952,338 compared to a net loss of $3,623,727 for the three-month period ended November 30, 2006. This decrease in net loss for the three-month period is primarily the result of lower research and development, general and administrative and interest expenses and the 2006 one time loss on extinguishment of debt of $782,143 relating to the repayment of the convertible bridge loan, partially offset by higher foreign exchange losses and income tax expense.

Revenue decreased to $1,144,094 for the year ended November 30, 2007, compared to $2,847,761 for the year ended November 30, 2006. The decrease during the year ended November 30, 2007, was primarily the result of the recognition of licensing fee revenue from Genentech in the fiscal 2006 period and a decrease in financial contributions from the National Research Council's Industrial Research Assistance Program, partially offset by the recognition of product and research contract revenue from the Takeda collaboration and the recognition of unearned revenue for PDL BioPharma Inc. in the fiscal 2007 period. For the three-month period ended November 30, 2007, the Company's revenue increased to $298,120 compared to $179,751 for the three-month period ended November 30, 2006. The increase was primarily the result of the recognition of product and research contract revenue fr
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... (PRWEB) August 26, 2014 The 20 ... of ALS (YFALS) community issued the following statement on ... bringing awareness and driving new funding specifically for ALS ... of water and some ice would raise all this ... with our families, and on behalf of the entire ...
(Date:8/26/2014)... Aug. 26, 2014  ViveBio, LLC a leading ... stabilization and transportation, announced today that it has ... LLC (LPS) of Knoxville, Tennessee ... the United States . ViveST ... ambient temperature dried biological specimen transport systems.  The ...
(Date:8/26/2014)... 26, 2014 Genedata, a leading ... and life science research, today announced the ... be held in Asia, Europe, and North America ... companies and leading research organizations will gather for ... case studies, and upcoming challenges in all areas ...
(Date:8/26/2014)... 26, 2014 Albany Molecular Research Inc. (NASDAQ: ... S. Marth , President and Chief Executive Officer at ... Conference on Monday, September 8, 2014 at 8:45 a.m. ... the presentation can be accessed at AMRI,s Investor Relations ... webcast will be archived for 90 days following the ...
Breaking Biology Technology:ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... LONDON, May 3, 2012 Silence Therapeutics ... company , notes that its partner, Quark Pharmaceuticals , ... with Pfizer. This amendment will enable Quark to perform a ... in a new indication, looking at visual function in patients ...
... 2, 2012 Genomic Health, Inc. (Nasdaq: ... a strategic alliance to use Next Generation Sequencing (NGS) ... clinical development of OncoMed,s  novel antibody cancer therapeutics. ... provide Genomic Health with breast, prostate, colon and lung ...
... April 30, 2012) Barrow Neurological Institute researchers Jorge Otero-Millan, ... of the Journal of Neuroscience in a ... Barrow is part of St. Joseph,s Hospital and Medical ... laboratory, explores the neural bases of illusory motion in ...
Cached Biology Technology:Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 2Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 4Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 2Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 3Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing 4Barrow researchers unravel illusion 2
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
(Date:8/26/2014)... a colony of harmful bacteria, biofilms make the ... in a biofilm pose a significant health risk ... treatment, and biofilm-protected bacteria account for some 80 ... are 50 to 1,000 times more resistant to ... we may have stumbled onto a magic bullet," ...
(Date:8/26/2014)... pressure from policymakers, consumers, and suppliers has prompted ... reducing the pollutants they emit from their smokestacks ... must also assess environmental performance at every step ... materials to the use and recycling of their ... the discipline known as life cycle engineering, which ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
... grain production must double by 2050 to address rising ... Illinois suggests crop yields will suffer unless new approaches ... Improved agronomic traits responsible for the remarkable increases in ... their ceiling for some of the world,s most important ...
... Ind. - Chemical engineers at Purdue University have developed ... biomass into biofuels, and they are proposing the creation ... to produce the fuels. "What,s important is ... -- wood chips, switch grass, corn stover, rice ...
... LAFAYETTE, Ind. - A Purdue University researcher can better retrieve ... using a newly developed technique and synthetic nanopolymer. W. ... be mapped and analyzed to find ways to inhibit the ... must be fished out of a sea of thousands of ...
Cached Biology News:'Business as usual' crop development won't satisfy future demand 2'Business as usual' crop development won't satisfy future demand 3New biofuels processing method for mobile facilities 2New biofuels processing method for mobile facilities 3New retrieval method makes studying cancer proteins easier 2
... These 1.5L PYREX trypsinizing ... homogenous tissue samples into cell ... proteins. Heavy beaded neck accepts ... enhance vigorous agitation. • Height ...
... For the efficient enrichment of functional ... or cell culture. The isolated ER ... and metabolic pathway analysis. Metabolic abnornalities ... in children, cystic fibrosis and many ...
Plasmid expressing PLAP reporter gene....
Plasmid expressing the LacZ reporter gene....
Biology Products: